MarketPulse

PARP inhibitor

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Allarity Therapeutics

Allarity Therapeutics Secures Patent Allowance for Stenoparib Companion Diagnostic

Allarity Therapeutics received USPTO notice of allowance for stenoparib DRP® companion diagnostic patent, providing exclusivity through 2039.
ALLRPhase 2 clinical trialstenoparib
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Allarity Therapeutics Secures $20M Funding to Accelerate Stenoparib FDA Path

Allarity Therapeutics secures $20M non-dilutive debt financing to complete stenoparib Phase 2 trial and advance toward FDA approval, extending runway to mid-2028.
ALLRFDA approvaldebt financing